Pergamum is currently operating at three sites, all closely tied to the leadig university hospitals in Sweden.
Dermagen
Lead indication: Atopic Dermatits
Stage of development: Clinical phase II
Origin: Lund University
Scientific founder:
Dr. Artur Schmidtchen, Lund University
Dr. Martin Malmsten, Uppsala University
Pharmasurgics
Lead indication: Post-Surgical Adhesions
Stage of development: Phase II
Origin: Göteborg University
Scientific founder:
Dr. Kjell Olmarker, Göteborg University
Dr. Inger Mattsby Baltzer, Göteborg University
Lipopeptide
Lead indication: Venous Leg Ulcers
Stage of development: Entering phase I
Origin: Karolinska Institutet in Stockholm
Scientific founder:
Dr. Mona Ståhle, Karolinska Institutet
Dr. Johan Heilborn, Karolinska Instituet
Pergamum was formed by merging and integrating PharmaSurgics AB, DermaGen AB, and Lipopeptide AB into one operational company.
The research behind all Pergamums’ development projects come from spear-head research groups at Swedens’ leading university hospitals.